Angelo Amabile, PhD
About Me
Dr. Angelo Amabile is a medical biotechnologist with a strong expertise in gene therapy and genetic engineering. His training began with a PhD in Molecular Medicine at San-Raffaele Telethon Institute for Gene Therapy (SR-TIGET) in Milan, a world leader Institute in the field of lentiviral-vector mediated gene therapy. His work established a new set of DNA editing tools, mainly based on CRISPR/Cas9, for genetic and epigenetic editing of mammalian cells. He subsequently joined Mount Sinai for his postdoctoral studies where he focused on RNA and Lipid Nanoparticles (LNP) technology. During his time at Sinai, Dr. Amabile developed a new technology for targeted delivery of LNPs for cell specific gene and cancer immunotherapy.
Dr. Amabile is Director of the NanoCore Facilty and a member of Icahn Genomics Institute.
Language
Position
About Me
Dr. Angelo Amabile is a medical biotechnologist with a strong expertise in gene therapy and genetic engineering. His training began with a PhD in Molecular Medicine at San-Raffaele Telethon Institute for Gene Therapy (SR-TIGET) in Milan, a world leader Institute in the field of lentiviral-vector mediated gene therapy. His work established a new set of DNA editing tools, mainly based on CRISPR/Cas9, for genetic and epigenetic editing of mammalian cells. He subsequently joined Mount Sinai for his postdoctoral studies where he focused on RNA and Lipid Nanoparticles (LNP) technology. During his time at Sinai, Dr. Amabile developed a new technology for targeted delivery of LNPs for cell specific gene and cancer immunotherapy.
Dr. Amabile is Director of the NanoCore Facilty and a member of Icahn Genomics Institute.
